Lack of MG53 in human heart precludes utility as a biomarker of myocardial injury or endogenous cardioprotective factor

Cardiovascular Research

Volumn 110, Issue 2, 2016, Pages 178-187

  Lemckert, Frances A ^a   Bournazos, Adam ^a   Eckert, Daniel M ^a   Kenzler, Manuel ^a   Hawkes, Joanne M ^a   Butler, Tanya L ^a   Ceely, Bradley ^a,b   North, Kathryn N ^a,b   Winlaw, David S ^a,b   Egan, Jonathan R ^a,b   Cooper, Sandra T ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

Author keywords

Biomarker of myocardial injury; Ischaemia reperfusion injury; Ischaemic preconditioning postconditioning; MG53; TRIM72

Indexed keywords

BIOLOGICAL MARKER; DYSFERLIN; MITSUGUMIN 53; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CARRIER PROTEIN; MG53 PROTEIN, MOUSE; MG53 PROTEIN, RAT; MITSUGUMIN 53, HUMAN; MUSCLE PROTEIN; VESICULAR TRANSPORT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; EPITOPE MAPPING; FUNCTIONAL DISEASE; HEART MUSCLE INJURY; HUMAN; HUMAN TISSUE; ISOLATED HEART; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; REPERFUSION INJURY; ANIMAL; CARDIAC MUSCLE; DISEASE MODEL; FEMALE; GENETICS; HEART; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOPHYSIOLOGY; PIG; SHEEP; SKELETAL MUSCLE;

ANIMALS; BIOMARKERS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; HEART; HUMANS; MALE; MICE; MUSCLE PROTEINS; MUSCLE, SKELETAL; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RATS; SHEEP; SWINE; VESICULAR TRANSPORT PROTEINS;

EID: 84966668589     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw017     Document Type: Article

References (15)

1. Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, Ko J-K, Lin P, Thornton A, Zhao X, Pan Z, Komazaki S, Brotto M, Takeshima H, Ma J. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol 2009;11:56-64.
2. Lek A, Evesson FJ, Lemckert FA, Redpath GMI, Lueders A-K, Turnbull L, Whitchurch CB, North KN, Cooper ST. Calpains, cleaved mini-dysferlinC72, and L-type channels underpin calcium-dependent muscle membrane repair. J Neurosci 2013;33:5085-5094.
3. Waddell LB, Lemckert FA, Zheng XF, Tran J, Evesson FJ, Hawkes JM, Lek A, Street NE, Lin P, Clarke NF, Landstrom AP, Ackerman MJ, Weisleder N, Ma J, North KN, Cooper ST. Dysferlin, annexin A1, and mitsugumin 53 are upregulated in muscular dystrophy and localize to longitudinal tubules of the T-system with stretch. J Neuropath Exp Neur 2011;70:302-313.
4. Wang X, Xie W, Zhang Y, Lin P, Han L, Han P, Wang Y, Chen Z, Ji G, Zheng M, Weisleder N, Xiao R-P, Takeshima H, Ma J, Cheng H. Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res 2010;107:76-83.
5. Cao C-M, Zhang Y,Weisleder N, Ferrante C,Wang X, Lv F, Zhang Y, Song R, Hwang M, Jin L, Guo J, Peng W, Li G, Nishi M, Takeshima H, Ma J, Xiao R-P. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 2010;121: 2565-2574.
6. Zhang Y, Lv F, Jin L, Peng W, Song R, Ma J, Cao C-M, Xiao R-P. MG53 participates in ischaemic postconditioning through the RISK signalling pathway. Cardiovasc Res 2011; 91:108-115.
7. Weisleder N, Takizawa N, Lin P,Wang X, Cao C, Zhang Y, Tan T, Ferrante C, Zhu H, Chen P-J, Yan R, Sterling M, Zhao X, Hwang M, Takeshima M, Cai C, Cheng H, Takeshima H, Xiao R-P, Ma J. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med 2012;4: 139-85.
8. Liu J, Zhu H, Zheng Y, Xu Z, Li L, Tan T, Park KH, Hou J, Zhang C, Li D, Li R, Liu Z, Weisleder N, Zhu D, Lin P, Ma J. Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury. J Mol Cell Cardiol 2015;80: 10-19.
9. Egan JR, Butler TL, Cole AD, Abraham S, Murala JS, Baines D, Street N, Thompson L, Biecker O, Dittmer J, Cooper S, Au CG, North KN, Winlaw DS. Myocardial membrane injury in pediatric cardiac surgery: an animal model. J Thorac Cardiov Surg 2009;137: 1154-1162.
10. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013;8:2281-2308.
11. Martindale JJ, Metzger JM. Uncoupling of increased cellular oxidative stress and myocardial ischemia reperfusion injury by directed sarcolemma stabilization. J Mol Cell Cardiol 2014;67:26-37.
12. Tzeng H-P, Evans S, Gao F, Chambers K, Topkara VK, Sivasubramanian N, Barger PM, Mann DL. Dysferlin mediates the cytoprotective effects of TRAF2 following myocardial ischemia reperfusion injury. J Am Heart Assoc 2014;3:000662.
13. Askenasy N, Vivi A, Tassini M, Navon G, Farkas DL. NMR spectroscopic characterization of sarcolemmal permeability during myocardial ischemia and reperfusion. J Mol Cell Cardiol 2001;33:1421-1433.
14. Barnabei MS, Palpant NJ, Metzger JM. Influence of genetic background on ex vivo and in vivo cardiac function in several commonly used inbred mouse strains. Physiol Genomics 2010;42A:103-113.
15. Kohr MJ. Mitsugumin-53: potential biomarker and therapuetic for myocardial ischaemic injury? J Mol Cell Cardiol 2015;81:46-48.